Arcadia Biosciences (RKDA) Non-Current Deffered Revenue (2014 - 2017)

Arcadia Biosciences' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $2.0 million for Q4 2017.

• Quarterly Non-Current Deffered Revenue fell 34.68% year-over-year to $2.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $2.0 million (down 34.68% YoY) and the FY2017 annual result came in at $2.0 million, down 34.68% from the prior year.
• Non-Current Deffered Revenue was $2.0 million for Q4 2017 at Arcadia Biosciences, down from $2.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $3.6 million in Q4 2014 and bottomed at $2.0 million in Q4 2017.
• A 4-year average of $2.8 million and a median of $2.8 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 28.44% in 2017, while the deepest fall reached 34.68% in 2017.
• Arcadia Biosciences' Non-Current Deffered Revenue stood at $3.6 million in 2014, then dropped by 27.48% to $2.6 million in 2015, then grew by 18.32% to $3.1 million in 2016, then sank by 34.68% to $2.0 million in 2017.
• Business Quant data shows RKDA's Non-Current Deffered Revenue at $2.0 million in Q4 2017, $2.8 million in Q3 2017, and $2.9 million in Q2 2017.